Kirkland, QC (April 12, 2018) - Pfizer Canada is experiencing supply constraints of EpiPen auto-injectors in the 0.3 mg and 0.15 mg formats. These supply constraints are due to delays at the manufacturing facility and limited third-party quantities of a component for the product.

Pfizer understands and regrets the challenges that these ongoing supply constraints pose to patients and the healthcare community.

Pfizer is working with its global network to recover supply of EpiPen products. In addition, Pfizer and Health Canada have been providing regular communication updates to key stakeholders on the supply status of EpiPen.

Available EpiPen supply in Canada will be managed through measured national allocation to wholesalers. This allocation is intended to support the provision of EpiPen auto-injectors to patients across the country.

- 30 -

For more information, please contact:

Questions of a Medical nature, please call: Pfizer Canada Medical Information @ 1-800-463-6001; www.pfizermedicalinformation.com

Questions from Trade customers, please call: Customer Relations @ 1-877-EPIPEN1 (1-877-374-7361).

If you are a member of the media, please call: Pfizer Canada Media Relations @ 1-866-9Pfizer (1-866-973-4937) email: [email protected]

About EpiPen: https://www.epipen.ca/en